Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines

Telehealth ketamine marketing compliance regulatory and ethical guidelines start with a simple rule: describe the treatment accurately, support health claims with appropriate evidence, and confirm that telemedicine statements match the rules where the patient is located. Ketamine clinics should distinguish FDA-approved uses of ketamine from off-label psychiatric uses, and they should not imply that FDA approval of esketamine applies to at-home racemic ketamine.

This guide covers FDA, FTC, DEA, REMS, and state-level issues that can affect advertising for telehealth ketamine services. It is educational information, not legal advice.

Start with the product and indication

The FDA explains that health care providers may prescribe an approved drug for an unapproved use when they judge it medically appropriate. Ketamine is FDA-approved as an anesthetic. Its use for depression, anxiety, or pain may be off-label, depending on the product and indication.

Esketamine is a different product. Spravato is an intranasal esketamine medicine with FDA-approved indications and a Risk Evaluation and Mitigation Strategy, known as REMS. Do not use Spravato's approval or REMS status to imply that at-home oral or sublingual racemic ketamine is FDA-approved for psychiatric treatment.

Patient-facing pages should identify the medicine, route of administration, treatment setting, approved or off-label status, and need for clinician assessment. Readers can review our guide to telehealth ketamine protocols for context on how clinical processes may be described.

Make health claims specific and supportable

The Federal Trade Commission expects advertisers to have competent and reliable scientific evidence before making health-related claims. The FTC's Health Products Compliance Guidance states that advertisers should match the strength and scope of a claim to the evidence supporting it.

A statement such as “ketamine has shown rapid antidepressant effects in clinical studies” differs materially from “ketamine will relieve your depression.” Avoid cure claims, guarantees, unsupported success rates, and comparisons that imply other treatments do not work. Explain that individual response, suitability, and risks vary. For research context, link readers to evidence on rapid antidepressant effects.

Testimonials and influencer content need the same review as website copy. A dramatic patient story can create a misleading overall impression when presented as an expected outcome. Material connections with endorsers should be disclosed, and statements about outcomes should have adequate support.

Account for controlled-substance and telemedicine requirements

According to the DEA's telemedicine guidance, ketamine is a Schedule III controlled substance. That guidance is an appropriate starting point for checking federal prescribing requirements, including temporary extensions or new rules. A marketing team should not assume that a pandemic-era workflow remains available.

State rules can add requirements related to clinician licensure, telemedicine consent, patient location, supervision, or prescribing. National campaigns may need state-specific eligibility language or landing pages. Confirm current requirements before using claims such as “fully online” or “no in-person visit required.”

Risk communication should be proportionate and visible. When relevant, direct readers to information on common ketamine side effectscardiovascular monitoring, and ketamine and alcohol safety risks.

Build a review process that can keep up

A practical program assigns clinical review for medical accuracy, compliance review for evidence and disclosures, and legal review for jurisdiction-specific questions. Keep a dated record of the final asset, supporting studies, required disclosures, reviewer approvals, and the states or audiences it targets.

For paid search and social advertising, review the ad and its destination page together. A necessary qualification should not appear only after a reader clicks through. Practices offering both racemic ketamine and esketamine should separate the services clearly so readers can understand their different settings and regulatory status.

The goal is not vague marketing. It is a clear, supportable explanation of what the service is, what is known, what remains uncertain, and what clinical evaluation is required.